[Enteric sorbents potentiate hepatoprotective effect of eplir in experimental toxic hepatitis].
The administration of eplir (a phospholipid-containing hepatoprotector), as well as of the enterosorbents polyphepan and EST-1 (an agent obtained from dry peat extract), to rats with tetrachloromethane-induced hepatitis protect the liver parenchyma against dystrophy, necrosis, and inflammation, reduce hyperfermentemia, decrease the blood bilirubin, ammonia, phenols, and malonaldehyde, and increase the urea content in blood serum, while not fully restoring all these biochemical parameters on the normal level. The treatment of rats with toxic hepatitis by a combination of eplir and enterosorbents is accompanied by a synergistic increase in the therapeutic efficacy of each component, leading to normalization of the biochemical parameters reflecting the functional slate of liver.
Vengerovskiĭ
A I
AI
Pharmacology Department, Siberian Medical University, Moskovskii Trakt 2, Tomsk, 634050 Russia.
Golovina
E L
EL
Burkova
V N
VN
Saratikov
A S
AS
D000818:Animals; D002252:Carbon Tetrachloride Poisoning / Q000473:pathology / Q000517:prevention & control; D002338:Carotenoids / Q000627:therapeutic use*; D056486:Chemical and Drug Induced Liver Injury / Q000473:pathology / Q000517:prevention & control*; D004338:Drug Combinations; D004357:Drug Synergism; D016061:Enterosorption; D008031:Lignin / Q000627:therapeutic use; D008099:Liver / Q000473:pathology; D008297:Male; D010743:Phospholipids / Q000627:therapeutic use*; D051381:Rats
D004338:Drug Combinations; D010743:Phospholipids; C064845:eplir; D002338:Carotenoids; C056995:polyfepan; D008031:Lignin